LMR Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

LMR Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.64M	Sell	20,700 -277,947	-93%	-$34.7M	0.01%	799
2025 Q4	$36.4M	Buy	+298,647	New	+$34.2M	0.07%	128
2025 Q2	–	Sell	-8,692	Closed	-$705K	–	1679
2025 Q1	$705K	Buy	+8,692	New	+$777K	0.01%	850
2024 Q4	–	Sell	-89,778	Closed	-$8.7M	–	1647
2024 Q3	$8.87M	Buy	+89,778	New	+$8.82M	0.07%	238
2024 Q1	–	Sell	-40,979	Closed	-$3.8M	–	1333
2023 Q4	$3.66M	Sell	40,979 -136,131	-77%	-$10.1M	0.04%	380
2023 Q3	$12.9M	Buy	+177,110	New	+$14.1M	0.15%	156
2023 Q2	–	Sell	-130,046	Closed	-$10.9M	–	1143
2023 Q1	$9.91M	Sell	130,046 -224,303	-63%	-$18.6M	0.15%	160
2022 Q4	$29.4M	Sell	354,349 -395,060	-53%	-$32M	0.51%	38
2022 Q3	$59.4M	Sell	749,409 -184,394	-20%	-$15.5M	1.09%	7
2022 Q2	$69.4M	Buy	933,803 +285,547	+44%	+$21.4M	1.16%	6
2022 Q1	$58.3M	Buy	648,256 +514,631	+385%	+$47.5M	0.68%	19
2021 Q4	$15M	Buy	133,625 +3,262	+3%	+$393K	0.15%	123
2021 Q3	$16.4M	Sell	130,363 -12,305	-9%	-$1.58M	0.18%	110
2021 Q2	$19.3M	Buy	+142,668	New	+$18.8M	0.29%	69

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LMR Partners's XBI Position: Q1 2026 in Review

LMR Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 93% in Q1 2026, selling an estimated $34.7M and leaving 20,700 shares worth $2.64M. The position accounts for 0.01% of the portfolio, ranked #799.

LMR Partners first reported a position in XBI in Q2 2021 and has held it in 14 quarters since. The position peaked at $69.4M in Q2 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

LMR Partners held 20,700 shares of State Street SPDR S&P Biotech ETF worth $2.64M as of Q1 2026.
LMR Partners sold 277,947 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $34.7M.
State Street SPDR S&P Biotech ETF made up 0.01% of LMR Partners's portfolio in Q1 2026, its #799 holding.
LMR Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 14 quarters since.
LMR Partners's State Street SPDR S&P Biotech ETF position peaked at $69.4M in Q2 2022.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.